Integrated Pharm Inc (INTP) 0.0009 $INTP
Intec Pharma Appoints VP of Clinical and Regulatory Affairs
PR Newswire - Tue May 03, 7:00AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs.
NTEC: 4.63 (-0.25)
Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients
PR Newswire - Mon Apr 04, 6:00AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its pivotal Phase III clinical trial for its lead product candidate, the Accordion Pill Carbidopa/Levodopa, or AP-CDLD, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.
NTEC: 4.63 (-0.25)
Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors
Marketwired - Thu Mar 17, 9:30AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Zvika Joseph has resigned from his position as director and Chairman of the board of directors. As reason for this step Mr. Joseph stated personal reasons.
NTEC: 4.63 (-0.25)
Intec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
Marketwired - Mon Mar 14, 6:30AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that its annual report on Form 20-F, containing audited financial statements for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 14, 2016, is available through its website (http://intecpharma.com). Shareholders may receive a hard copy of the annual report free of charge upon request to the Company.
NTEC: 4.63 (-0.25)
Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product
Marketwired - Thu Mar 10, 7:00AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical trial with its third pipeline product.
NTEC: 4.63 (-0.25)
Intec Pharma to Present at Biotech Showcase 2016
Marketwired - Tue Jan 05, 6:00AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, Zeev Weiss, will present at Biotech Showcase on January 13, 2016 at 10:30 a.m. PT. The conference will be held in San Francisco, CA.
NTEC: 4.63 (-0.25)
Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe
Marketwired - Wed Dec 16, 6:00AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European Patent Office (EPO) that a European patent will be granted December 23, 2015 on the Company's European Patent Application for a "Zaleplon gastroretentive drug delivery system."
NTEC: 4.63 (-0.25)
Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease
Marketwired - Mon Dec 14, 7:10AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has received a US centralized institutional review board (IRB) approval to initiate its Phase III clinical trial for its lead product, the Accordion Pill Carbidopa/Levodopa, or AP-CDLD, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.
NTEC: 4.63 (-0.25)
Intec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product
Marketwired - Tue Dec 08, 7:30AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it is entering a Phase I clinical trial with its third pipeline product.
NTEC: 4.63 (-0.25)
Intec Pharma Reports Results for the Third Quarter of 2015
Marketwired - Thu Nov 05, 3:30PM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) ("Intec Pharma" or the "Company"
, an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the third quarter ended September 30, 2015 and provided a business update. Results are presented in New Israel Shekels (NIS) with a convenience translation to US$ provided using the Bank of Israel exchange rate of NIS 3.923 to $1.00 at September 30, 2015.
NTEC: 4.63 (-0.25)
Intec Pharma Appoints VP of Clinical and Regulatory Affairs
PR Newswire - Tue May 03, 7:00AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs.
NTEC: 4.63 (-0.25)
Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients
PR Newswire - Mon Apr 04, 6:00AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its pivotal Phase III clinical trial for its lead product candidate, the Accordion Pill Carbidopa/Levodopa, or AP-CDLD, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.
NTEC: 4.63 (-0.25)
Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors
Marketwired - Thu Mar 17, 9:30AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Zvika Joseph has resigned from his position as director and Chairman of the board of directors. As reason for this step Mr. Joseph stated personal reasons.
NTEC: 4.63 (-0.25)
Intec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
Marketwired - Mon Mar 14, 6:30AM CDT
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that its annual report on Form 20-F, containing audited financial statements for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 14, 2016, is available through its website (http://intecpharma.com). Shareholders may receive a hard copy of the annual report free of charge upon request to the Company.
NTEC: 4.63 (-0.25)
Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product
Marketwired - Thu Mar 10, 7:00AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical trial with its third pipeline product.
NTEC: 4.63 (-0.25)
Intec Pharma to Present at Biotech Showcase 2016
Marketwired - Tue Jan 05, 6:00AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, Zeev Weiss, will present at Biotech Showcase on January 13, 2016 at 10:30 a.m. PT. The conference will be held in San Francisco, CA.
NTEC: 4.63 (-0.25)
Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe
Marketwired - Wed Dec 16, 6:00AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European Patent Office (EPO) that a European patent will be granted December 23, 2015 on the Company's European Patent Application for a "Zaleplon gastroretentive drug delivery system."
NTEC: 4.63 (-0.25)
Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease
Marketwired - Mon Dec 14, 7:10AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has received a US centralized institutional review board (IRB) approval to initiate its Phase III clinical trial for its lead product, the Accordion Pill Carbidopa/Levodopa, or AP-CDLD, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.
NTEC: 4.63 (-0.25)
Intec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product
Marketwired - Tue Dec 08, 7:30AM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it is entering a Phase I clinical trial with its third pipeline product.
NTEC: 4.63 (-0.25)
Intec Pharma Reports Results for the Third Quarter of 2015
Marketwired - Thu Nov 05, 3:30PM CST
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) ("Intec Pharma" or the "Company"
, an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the third quarter ended September 30, 2015 and provided a business update. Results are presented in New Israel Shekels (NIS) with a convenience translation to US$ provided using the Bank of Israel exchange rate of NIS 3.923 to $1.00 at September 30, 2015. NTEC: 4.63 (-0.25)
